India Pharma Outlook Team | Wednesday, 01 June 2022
BDR Pharmaceuticals and Varenyam Healthcare have announced the launch of Sugammadex - an innovative, first of its kind drug in over 10 years with novel γ-cyclodextrin neuromuscular block (NMB) reversal properties. Sugammadex is a pioneer in anaesthetic drugs, offering safe, rapid and complete reversal of shallow, moderate and deep neuromuscular block (NMB) and removes anaesthetic effects from the body.
Reversal agents which are currently available in the market cannot reverse deep NMB, and thus lead to various postoperative respiratory complications. If used clinically, this drug is the solution to the fatal shortcomings of current anaesthetic practices.
Sugammadex is available as 2ml & 5ml single-dose vials. Commenting on the launch, Raheel Shah, Director, Business Development, BDR Pharmaceuticals Int’l PvtLtd, said, “The results collated from the Indian trials on patients promise to be advantageous for the users with no additional side effects. Sugammadex is set to be the game changer in the segment of reversal agents in modern day surgery.
This product is testament to our objective of bringing innovation with the introduction of novel drugs which were not present in the domestic market previously.” This first of its kind new generation drug in India, Sugammadex is going to be more efficient, effective and life-saving for patients with severe complications thereby improving the overall rate of recovery. Bhahim Desai, CEO, Varenyam Healthcare Private Limited commented, “Varenyam has a standing commitment to the medical fraternity to bring ambulatory anaesthesia practices to India.
This alliance shows our commitment to bringing innovation & excellence into safe and novel anaesthetic practices in India. Varenyam’s trained and experienced sales team, specialised in promotion and ethical sales of anaesthetic drugs, will be able to penetrate the deep end of the market.”
, CDSCO.jpg)
.jpg)